Ginkgo Bioworks (DNA) Competitors $6.95 -0.17 (-2.43%) As of 09:44 AM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock DNA vs. VERA, GLPG, KNSA, SDGR, IDYA, AAPG, WVE, IMCR, ANIP, and DYNShould you be buying Ginkgo Bioworks stock or one of its competitors? The main competitors of Ginkgo Bioworks include Vera Therapeutics (VERA), Galapagos (GLPG), Kiniksa Pharmaceuticals (KNSA), Schrödinger (SDGR), IDEAYA Biosciences (IDYA), Ascentage Pharma Group International (AAPG), Wave Life Sciences (WVE), Immunocore (IMCR), ANI Pharmaceuticals (ANIP), and Dyne Therapeutics (DYN). These companies are all part of the "pharmaceutical products" industry. Ginkgo Bioworks vs. Vera Therapeutics Galapagos Kiniksa Pharmaceuticals Schrödinger IDEAYA Biosciences Ascentage Pharma Group International Wave Life Sciences Immunocore ANI Pharmaceuticals Dyne Therapeutics Vera Therapeutics (NASDAQ:VERA) and Ginkgo Bioworks (NYSE:DNA) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their dividends, community ranking, earnings, risk, analyst recommendations, valuation, institutional ownership, profitability and media sentiment. Does the media prefer VERA or DNA? In the previous week, Vera Therapeutics had 5 more articles in the media than Ginkgo Bioworks. MarketBeat recorded 5 mentions for Vera Therapeutics and 0 mentions for Ginkgo Bioworks. Vera Therapeutics' average media sentiment score of 1.74 beat Ginkgo Bioworks' score of 0.33 indicating that Vera Therapeutics is being referred to more favorably in the media. Company Overall Sentiment Vera Therapeutics Very Positive Ginkgo Bioworks Neutral Do insiders & institutionals have more ownership in VERA or DNA? 99.2% of Vera Therapeutics shares are held by institutional investors. Comparatively, 78.6% of Ginkgo Bioworks shares are held by institutional investors. 21.7% of Vera Therapeutics shares are held by insiders. Comparatively, 9.7% of Ginkgo Bioworks shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term. Which has stronger valuation and earnings, VERA or DNA? Vera Therapeutics has higher earnings, but lower revenue than Ginkgo Bioworks. Vera Therapeutics is trading at a lower price-to-earnings ratio than Ginkgo Bioworks, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioVera TherapeuticsN/AN/A-$95.99M-$2.75-9.80Ginkgo Bioworks$227.04M1.78-$892.87M-$10.68-0.65 Which has more risk and volatility, VERA or DNA? Vera Therapeutics has a beta of 1.17, suggesting that its share price is 17% more volatile than the S&P 500. Comparatively, Ginkgo Bioworks has a beta of 1.23, suggesting that its share price is 23% more volatile than the S&P 500. Does the MarketBeat Community prefer VERA or DNA? Vera Therapeutics received 17 more outperform votes than Ginkgo Bioworks when rated by MarketBeat users. Likewise, 66.13% of users gave Vera Therapeutics an outperform vote while only 46.15% of users gave Ginkgo Bioworks an outperform vote. CompanyUnderperformOutperformVera TherapeuticsOutperform Votes4166.13% Underperform Votes2133.87% Ginkgo BioworksOutperform Votes2446.15% Underperform Votes2853.85% Do analysts recommend VERA or DNA? Vera Therapeutics currently has a consensus target price of $64.67, indicating a potential upside of 140.00%. Ginkgo Bioworks has a consensus target price of $4.58, indicating a potential downside of 34.14%. Given Vera Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Vera Therapeutics is more favorable than Ginkgo Bioworks.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Vera Therapeutics 0 Sell rating(s) 1 Hold rating(s) 6 Buy rating(s) 3 Strong Buy rating(s) 3.20Ginkgo Bioworks 3 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 1.60 Is VERA or DNA more profitable? Vera Therapeutics has a net margin of 0.00% compared to Ginkgo Bioworks' net margin of -298.78%. Vera Therapeutics' return on equity of -50.13% beat Ginkgo Bioworks' return on equity.Company Net Margins Return on Equity Return on Assets Vera TherapeuticsN/A -50.13% -39.50% Ginkgo Bioworks -298.78%-58.54%-34.24% SummaryVera Therapeutics beats Ginkgo Bioworks on 14 of the 18 factors compared between the two stocks. Remove Ads Get Ginkgo Bioworks News Delivered to You Automatically Sign up to receive the latest news and ratings for DNA and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart DNA vs. The Competition Export to ExcelMetricGinkgo BioworksBiological Products IndustryMedical SectorNYSE ExchangeMarket Cap$404.67M$3.03B$5.68B$19.75BDividend YieldN/A1.54%4.55%3.75%P/E Ratio-0.5329.9524.6034.05Price / Sales1.78447.85388.5928.57Price / CashN/A168.6838.1617.54Price / Book0.324.227.084.63Net Income-$892.87M-$71.72M$3.19B$1.02B7 Day Performance-7.68%-3.44%-0.93%0.14%1 Month Performance-24.15%-9.94%3.56%-2.36%1 Year PerformanceN/A-23.03%14.29%7.29% Ginkgo Bioworks Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)DNAGinkgo Bioworks0.5417 of 5 stars$6.95-2.4%$4.58-34.1%N/A$404.67M$227.04M-0.53640VERAVera Therapeutics3.219 of 5 stars$27.25+0.6%$64.67+137.3%-34.6%$1.74BN/A-10.4740Positive NewsGLPGGalapagos0.3889 of 5 stars$25.91+0.4%$26.75+3.2%-21.9%$1.71B$275.65M0.001,123Positive NewsKNSAKiniksa Pharmaceuticals2.9016 of 5 stars$23.47+0.4%$37.17+58.4%+16.2%$1.70B$423.24M-167.45220SDGRSchrödinger2.6684 of 5 stars$22.66+3.9%$32.29+42.5%-15.9%$1.66B$207.54M-9.74790Positive NewsGap UpIDYAIDEAYA Biosciences3.5154 of 5 stars$18.67+1.5%$53.58+187.1%-57.4%$1.64B$7M-5.6680News CoveragePositive NewsAAPGAscentage Pharma Group InternationalN/A$18.65-0.3%N/AN/A$1.62B$903.03M0.00600WVEWave Life Sciences4.5521 of 5 stars$10.02+4.5%$22.60+125.5%+63.3%$1.54B$108.30M-9.04240Positive NewsIMCRImmunocore2.1162 of 5 stars$29.58-0.8%$65.64+121.9%-53.1%$1.48B$310.20M-31.19320Positive NewsANIPANI Pharmaceuticals3.6075 of 5 stars$64.85+0.9%$79.75+23.0%-4.7%$1.42B$614.38M-118.62600Positive NewsDYNDyne Therapeutics3.2595 of 5 stars$12.27+1.5%$47.46+287.0%-56.3%$1.39BN/A-3.45100 Remove Ads Related Companies and Tools Related Companies Vera Therapeutics Competitors Galapagos Competitors Kiniksa Pharmaceuticals Competitors Schrödinger Competitors IDEAYA Biosciences Competitors Ascentage Pharma Group International Competitors Wave Life Sciences Competitors Immunocore Competitors ANI Pharmaceuticals Competitors Dyne Therapeutics Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NYSE:DNA) was last updated on 3/26/2025 by MarketBeat.com Staff From Our PartnersDOGE could send 6 AI stocks through the roofStay alert for Elon Musk and the Department of Government Efficiency's next move … Expect an announcement f...Weiss Ratings | SponsoredTrump’s Secret WeaponHave you looked at the stock market recently? Millions of investors are scrambling trying to figure out what's...American Alternative | SponsoredDo this Before Elon's Reveal on April 23rdElon’s newest tech could pay you an extra $30,000 a year — while you sleep. It’s smaller than a quarter but...Brownstone Research | SponsoredNew “Trump” currency proposed in DCAccording to one of the most connected men in Washington… A surprising new bill was just introduced in Wash...Paradigm Press | SponsoredTrump’s Bitcoin Reserve is No Accident…Bryce Paul believes this is the #1 coin to buy right now The catalyst behind this surge is a massive new b...Crypto 101 Media | SponsoredWhy Elon put $51 million into thisWhy Elon Musk Just Invested $51 Million Into Brand New “Miracle Metal” Developed by MIT ScientistsTrue Market Insiders | SponsoredMost gold “analysts” aren’t really gold analysts… [watch out]People who don’t understand the gold market are about to lose a lot of money. Unfortunately, most so-called “g...Golden Portfolio | SponsoredAlert: DOGE goes liveElon will most likely be at the helm of it all. And just days from now, could bring about the biggest econo...Altimetry | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Ginkgo Bioworks Holdings, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Ginkgo Bioworks With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
